Clinical Research Directory
Browse clinical research sites, groups, and studies.
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Sponsor: Gamida Cell ltd
Summary
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
Official title: An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Key Details
Gender
All
Age Range
12 Years - Any
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2020-07-08
Completion Date
2025-05-08
Last Updated
2026-06-22
Healthy Volunteers
No
Conditions
Interventions
omidubicel
hematopoietic stem cell transplant
Locations (6)
UCLA
Los Angeles, California, United States
Stanford University Cancer Institute
Palo Alto, California, United States
Loyola University, Cardinal Bernardin Cancer Center
Maywood, Illinois, United States
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, United States
Duke University Medical Center
Durham, North Carolina, United States
Oregon Health & Science University
Portland, Oregon, United States